Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

This is a multi-center, single arm study to evaluate the efficacy and safety of donafenib in combination with envafolimab treatment in patients with high risk of recurrent hepatocellular carcinoma after radical surgery.

Trial Details

NCT ID
NCT06498622
Phase
PHASE2
Sponsor
Anhui Provincial Hospital
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Donafenib + Envafolimab
Locations (sample)
  • Fuyang, Anhui, China|32.9,115.81667
  • Hefei, Anhui, China|31.86389,117.28083

Key Eligibility Criteria

  • 18-80 years old, male and female.
  • Subjects voluntarily enrolled in this study and signed the informed consent, good compliance and co-operated with the follow-up.
  • Primary hepatocellular carcinoma with postoperative histopathological diagnosis of HCC and negative margins.
  • Presence of any of the following high-risk factors for recurrence: ① tumor size ≥5.0cm combined with microvascular invasion; ② number of tumors ≥3;…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →